GeneQuine Biotherapeutics GmbH
Company
Log in or create an account to access this page
Join EuroQuity to access the content on this page and benefit usage of networking features.
- Find the right partners
- Stay informed about your ecosystem
- Access exclusive events
Signing up is quick and free!
About
GeneQuine develops next generation gene therapy for musculoskeletal diseases with a potentially disease-modifying lead candidate for osteoarthritis.
In 2017, GeneQuine sold its (then-) lead program for osteoarthritis to Flexion Therapeutics Inc. for up to $64 million.
GeneQuine is currently raising a series A of €16 million to take its second gene therapy drug candidate for osteoarthritis to the clinic, to start a development program for degenerative disc disease, and to expand its lab.
Network (0)
There are no organizations in the network.
There are currently no users in this organisation.
